The analysis showed an approximate 40% reduction in the risk of disease recurrence or death after surgery among patients who received at least one dose of adjuvant nivolumab following neoadjuvant ...

There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone ...

"This is the first and only clinical trial so far to test the novel combination of nivolumab and the experimental drug vidutolimod in the neoadjuvant setting," said lead author Diwakar Davar ...